Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Chaudhary, Ajay K ^a,b   Singh, Mamta ^b   Bharti, Alok C ^c   Singh, Mangal ^b   Shukla, Shirish ^c   Singh, Atul K ^a   Mehrotra, Ravi ^b  

^a UNIVERSITY OF ALLAHABAD   (India)

^b MLN MEDICAL COLLEGE   (India)

^c NOIDA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; STROMELYSIN; TUMOR MARKER;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BETEL NUT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK DISEASE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKELESS TOBACCO; SMOKING; CANCER STAGING; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NEOPLASM STAGING; ORAL SUBMUCOUS FIBROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77950460668     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-369     Document Type: Article

References (39)

1. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99(2):157-66. 10.1002/ijc.10329, 11979428.
2. Matrisian LM. Cancer biology. Extracellular proteinases in malignancy. Curr Biol 1999, 9:776-778.
3. Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Larjava H, Isaka K, Saarialho-Kere U. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004, 202(1):14-22. 10.1002/path.1479, 14694517.
4. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000, 6(12):4823-4830.
5. Johanssona N, Ahonenb M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000, 57:5-15. 10.1007/s000180050495, 10949577.
6. Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 2003, 278:37849-37857. 10.1074/jbc.M302946200, 12867428.
7. Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci 2010, 17:10. 10.1186/1423-0127-17-10, 2846899, 20152059.
8. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999, 31:34-45. 10.3109/07853899909019260, 10219712.
9. Zinzindohouém F, Blons H, Hans S, Loriot MA, Houllier AM, Brasnu D, Laccourreye O, Tregouet DA, Stucker I, Laurent-Puig P. Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res 2004, 24(3b):2021-6.
10. Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, Ueyama Y, Shinozaki F, Yamashita H, Hinoda Y. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett 2004, 211(1):19-24. 10.1016/j.canlet.2004.01.032, 15194213.
11. Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005, 26:481-486. 10.1093/carcin/bgh327, 15528217.
12. Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 2002, 8(12):3820-3823.
13. Ashworth JL, Murphy G, Rock MJ. Fibrillin degradation by matrix metalo protienase: Implication for connective tissue remodelling. Biochem J 1999, 340(Pt 1):171-81. 10.1042/0264-6021:3400171, 1220235, 10229672.
14. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996, 271(22):13055-13060. 10.1074/jbc.271.22.13244, 8662692.
15. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report; genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995, 73:209-15. 10.1136/hrt.73.3.209, 483800, 7727178.
16. Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, Liu G, Christiani DC. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006, 27:1024-1029. 10.1093/carcin/bgi283, 16311244.
17. Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud R, Mattioli PL, Federici G. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000, 20:1600-1605.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2003, 100:57-70.
19. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 2003, 106(5):683-689. 10.1002/ijc.11283, 12866027.
20. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 2004, 33:405-9. 10.1111/j.1600-0714.2004.00231.x, 15250832.
21. Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ, Chang KW. Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med 2004, 33:323-6.
22. Tu HF, Liu CJ, Chang CS, Lui MT, Kao SY, Chang CP, Liu TY. The functional -1171 (5A/6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. Oral Pathol Med 2006, 3(5):99-103.
23. Pandya S, Chaudhary AK, Sngh M, Mehrotra R. Correlation of histopathological diagnosis with habits and clinical findings in oral submucous fibrosis. Head & neck Oncology 2009, 1(1):11. 2686689, 19432960, 10.1186/1758-3284-1-10.
24. Chiu CJ, Chiang CP, Chang ML. Association between genetic polymorphism of tumour necrosis factor-alpha and risk of oral submucous fibrosis, a pre cancerous condition of oral cancer. J Dent Res 2001, 80(12):2055-2059. 10.1177/00220345010800120601, 11808761.
25. Shin YN, Lin CJ, Chang KW, Lee YJ, Liu HF. Association of CTLA-4 gene polymorphism with oral submucous fibrosis in Taiwan. J Oral Pathol Med 2004, 33:200-3. 10.1111/j.0904-2512.2004.00081.x, 15061706.
26. Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, Serefoglou Z, Vorris E. Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increase risk for oral cancer. Anticancer Res 2007, 27(6B):4095-100.
27. Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005, 26:481-486. 10.1093/carcin/bgh327, 15528217.
28. Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, Wang N, Wang Y, Wen D, Wei L, Kuang G, Dong Z. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 2004, 25:2519-2524. 10.1093/carcin/bgh269, 15319302.
29. Blons H, Gad S, Zinzindohoué F, Manière I, Beauregard J, Tregouet D, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res 2004, 10(8):2594-9. 10.1158/1078-0432.CCR-1116-03, 15102660.
30. Smolarz B, Szyłło K, Romanowicz-Makowska H, Niewiadomski M, Kozłowska E, Kulig A. PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol 2003, 54(4):233-8.
31. Yoon S, Tromb G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H. Genetic analysis of MMP3 and MMP9 and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Communic 1999, 265:563-568.
32. Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, Hazama S, Kitamura Y, Kamatani N, Oka M. Association of functional polymorphisms of matrix metalloproteinase-1 (MMP-1) and MMP-3 genes with colorectal cancer. Int J Cancer 2002, 102:526-529. 10.1002/ijc.10750, 12432557.
33. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004, 138(2):357-63. 10.1111/j.1365-2249.2004.02615.x, 1809204, 15498049.
34. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrixmetalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999, 14(2):138-45. 10.1046/j.1440-1746.1999.01821.x, 10029294.
35. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003, 92:827-839. 10.1161/01.RES.0000070112.80711.3D, 12730128.
36. Strup-Perrot C, Mathé D, Linard C, Violot D, Milliat F, François A, Bourhis J, Vozenin-Brotons MC. Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis. Am J Physiol Gastrointest Liver Physiol 2004, 287(4):G875-85. 10.1152/ajpgi.00088.2004, 15178550.
37. Chang YC, Yang SF, Tai KW, Chou MY, Hsieh S. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase: A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol 2002, 38(2):195-200. 10.1016/S1368-8375(01)00045-8, 11854068.
38. Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, Kubota T, Itagaki M, Shingaki S, Ohnishi M, Kurita H, Katsura K, Saito C, Yoshie H, Takagi R. The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer 2007, 7:187. 10.1186/1471-2407-7-187, 2089080, 17919326.
39. McCawley L, Crawford H, King L, Mudgett J, Matrisian L. Aprotective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004, 64:6965-6972. 10.1158/0008-5472.CAN-04-0910, 15466188.